FDG PET/CT for Cardiac Sarcoidosis

Introduction

Cardiac FDG PET/CT for sarcoidosis lives or dies on dietary preparation: the entire point is to starve normal heart muscle of glucose so that inflammatory cells light up against a dark background. When preparation succeeds, the study is one of the most powerful tools in cardiac imaging for detecting active inflammation. When it fails, the heart glows uniformly and the study is non-diagnostic — or worse, falsely positive.

Cardiac sarcoidosis is a diagnostic challenge. It can cause heart block, ventricular arrhythmias, and sudden death, sometimes before any systemic sarcoidosis is recognized, and endomyocardial biopsy has low sensitivity because the disease is patchy. ⁵ Fluorine-18 fluorodeoxyglucose (FDG) PET/CT, paired with a rest perfusion study, can reveal active myocardial inflammation and guide immunosuppressive therapy and device decisions. ^{1, 2}

But FDG is a glucose analog, and normal myocardium is metabolically flexible: it will happily burn glucose, take up FDG, and hide the very disease you are looking for. The physics and physiology of suppressing that normal uptake are what separate a diagnostic cardiac sarcoid study from a wasted injection. This guide explains the substrate-suppression mechanism, compares dietary protocols against published suppression rates, works through SUV quantitation, and covers dose and QC. DRPS supports cardiac PET programs through PET/CT and nuclear medicine physics services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What the study is trying to show

Cardiac FDG PET for sarcoidosis is an inflammation-imaging study, not a perfusion study, and it is almost always interpreted alongside a rest myocardial perfusion image. The combination answers two questions at once: is there scar or reduced perfusion, and is there active, FDG-avid inflammation? ^{1, 2}

The canonical patterns are:

• Normal perfusion, no FDG uptake (well suppressed): no evidence of active cardiac sarcoidosis.
• Perfusion defect with focal FDG uptake (mismatch): suggests active inflammation, often the highest-risk pattern.
• Focal or focal-on-diffuse FDG uptake: suspicious for active disease when suppression is adequate.
• Diffuse uniform FDG uptake: usually means preparation failed, not that the whole heart is inflamed. ¹

That last pattern is the trap. Distinguishing true diffuse disease from failed suppression is often impossible, which is why the quality of dietary preparation is not a logistics detail — it is part of the diagnosis. For background on how FDG behaves in PET generally, see F-18 FDG PET dose optimization and PET SUV quantification.

Why normal myocardium must be suppressed

The heart is an omnivore. In the fed state, with insulin elevated, myocardium preferentially uses glucose. In the fasted state, or under a high-fat, low-carbohydrate load, it shifts to free fatty acid (FFA) oxidation and largely stops importing glucose. Inflammatory cells — activated macrophages in sarcoid granulomas — are different: they are obligate, high-rate glucose consumers through up-regulated glucose transporters (GLUT-1 and GLUT-3) and hexokinase, and they keep taking up FDG even when normal myocardium has switched to fat. ^{1, 2}

So the preparation strategy is a metabolic switch: drive normal myocardium to FFA metabolism so it goes dark, while inflammation stays bright. The contrast between the two is the signal.

Key Technical Principles

The substrate-suppression mechanism

FDG is transported into cells like glucose and phosphorylated by hexokinase to FDG-6-phosphate, which is then metabolically trapped (it is not a substrate for the next glycolytic step). The rate of trapping depends on glucose-transporter expression and competing serum glucose. Two levers shift normal myocardium away from FDG uptake:

• High fat, very low carbohydrate intake raises circulating FFAs and lowers insulin, pushing myocardium toward fatty-acid oxidation.
• Prolonged fasting depletes glycogen and further lowers insulin, reinforcing the switch.

Some protocols add intravenous unfractionated heparin before injection to raise plasma FFAs through lipolysis, further promoting fatty-acid metabolism in normal myocardium. ¹ Inflammatory macrophages do not make this switch; they remain glucose-dependent, so the preparation widens the gap between background and disease.

Dietary protocols and their suppression rates

Protocols vary in strictness and duration, and the evidence favors longer, stricter preparation. The table below summarizes published approaches and reported complete-suppression performance. ^{1, 3, 4}

The clinical message is consistent: a single overnight fast is not enough, and a structured, high-fat, very-low-carbohydrate preparation substantially improves the odds of a diagnostic study. ^{1, 3}

Quantitation: the SUV and what can corrupt it

The standardized uptake value (SUV) normalizes measured activity concentration to injected activity and body size, so that uptake can be compared across patients and over time. It is defined as:

where $C_t$ is the decay-corrected tissue activity concentration (kBq/mL), $A_{\text{inj}}$ is the injected activity (kBq), and $W$ is body weight (g), taking 1 mL of tissue as 1 g. As a worked example, suppose a myocardial focus has $C_t=8.0$ kBq/mL, the injected activity is $A_{\text{inj}}=370\text{MBq}=3.7\times 10^5$ kBq, and the patient weighs $W=80\text{kg}=8.0\times 10^4$ g:

For interpretation, that focal SUV is compared against a reference such as blood-pool or liver. A useful derived index is the target-to-background ratio:

Every term in the SUV equation is an error source. If injected activity is overstated because residual activity left in the syringe and tubing is not subtracted, SUV is biased low. If patient weight is stale, SUV is wrong. If the scanner and dose calibrator are not cross-calibrated, every SUV is off by the calibration error. Consistent technique is especially critical for therapy monitoring, where a change in SUV is interpreted as a change in disease. ¹

Dose

Using the ICRP Publication 128 adult effective-dose coefficient for F-18 FDG of about $1.9\times 10^{-2}$ mSv/MBq, a 370 MBq injection delivers approximately: ⁶

The CT component adds to this. A low-dose CT used only for attenuation correction and localization adds relatively little, while a diagnostic-quality CT adds substantially more, so the protocol should match the CT technique to the clinical question. For the general approach to trimming FDG dose, see F-18 FDG PET dose optimization.

Clinical Impact

Why this study changes management

Cardiac sarcoidosis can present as conduction disease, ventricular arrhythmia, or unexplained cardiomyopathy in a relatively young patient. Identifying active inflammation matters because active disease may respond to immunosuppression, and the presence and extent of inflammation inform device (pacemaker or defibrillator) decisions. ^{2, 5} FDG PET is one of the few tools that images activity rather than just structure or scar, and it can track response to therapy over time when preparation and quantitation are held constant. ¹

The cost of a failed study

A non-diagnostic cardiac FDG PET is not a neutral outcome. It means:

• a wasted radiopharmaceutical dose and CT exposure,
• a delayed or uncertain diagnosis in a patient who may be at risk of sudden death, and
• a potential false positive if diffuse uptake is misread as disease.

Published series show the failure rate is preparation-dependent: with a ketone-based formula preparation, about 7.1% of studies were non-diagnostic due to failed suppression, and the rate was similar in patients with diabetes. ⁴ A weak 18-hour-fast-only protocol fails far more often. ³ This is why the physics and logistics of preparation deserve the same rigor as the scan itself.

Consistency for therapy monitoring

When a patient is scanned before and after starting immunosuppression, the comparison is only valid if the two studies used the same preparation, the same injected activity target, and the same quantitation. A patient who followed the diet strictly the first time and loosely the second will appear to have "more inflammation" purely as an artifact of preparation. For programs doing serial imaging, a written, enforced preparation protocol is a quantitation tool, not just a patient-instruction sheet.

Practical Optimization Tips

1. Make the preparation strict and written

Adopt a high-fat, very-low-carbohydrate diet for at least 24 hours (longer is better), followed by prolonged fasting, and give patients concrete food lists rather than vague instructions. The evidence strongly favors stricter, longer preparation. ^{1, 3}

2. Check a pre-scan glucose and document it

Elevated serum glucose promotes myocardial FDG uptake and undermines suppression. Record the value so a later diffuse-uptake pattern can be interpreted in context.

3. Subtract residual activity

Measure and subtract syringe and line residual activity from the injected-activity entry, or SUV will be biased. Keep clocks on the dose calibrator and scanner synchronized for correct decay correction.

4. Cross-calibrate the scanner and dose calibrator

SUV is only as trustworthy as the scanner-to-dose-calibrator cross-calibration. This is a routine but essential QC step for any quantitative PET program. ⁷

5. Always pair with perfusion

Interpret FDG against a rest perfusion study. The mismatch pattern is the diagnostic backbone, and FDG alone is much harder to read. ^{1, 2}

Common pitfalls to avoid

• Treating preparation as optional. An overnight fast alone fails in roughly half of patients. ³
• Misreading diffuse uptake as disease. Diffuse uptake usually means failed suppression.
• Inconsistent preparation between serial scans. This corrupts therapy monitoring.
• Sloppy injected-activity accounting. Residual activity and clock errors distort SUV.
• Skipping the perfusion study. FDG without perfusion loses the mismatch logic.

Regulatory Considerations

Cardiac FDG PET/CT is governed by professional procedure standards and by the radiopharmaceutical dose framework, layered on top of the facility's radioactive material license. The program should be documented against the following: ^{1, 2, 6}

• SNMMI–ASNC Expert Consensus Document on the role of F-18 FDG PET/CT in cardiac sarcoid detection and therapy monitoring — the primary consensus guiding indications, preparation, acquisition, and interpretation. ^{1, 2}
• SNMMI Procedure Standards and ASNC Imaging Guidelines — define acquisition, processing, and quality expectations for PET and nuclear cardiology procedures. ^{8, 9}
• ICRP Publication 128 — the reference compendium for radiopharmaceutical dose coefficients used to estimate patient effective dose. ⁶

Because FDG is byproduct material, the clinical use also falls under the facility's radioactive material license and the medical-use rules (10 CFR Part 35 for NRC facilities, or the equivalent Agreement State program). Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control programs, while Washington, DC and Delaware are regulated directly by the NRC. A facility should connect its cardiac PET quantitation program to PET/CT and nuclear medicine physics support and to accreditation support where applicable. For the broader dose context, see Radiopharmaceutical dosimetry and ICRP 128.

Frequently Asked Questions (FAQs)

Why does cardiac FDG PET require special dietary preparation?

Normal heart muscle can burn either glucose or free fatty acids. If the myocardium is using glucose when FDG is injected, the whole heart lights up and inflammation is hidden. Dietary preparation — a high-fat, very-low-carbohydrate diet followed by prolonged fasting — shifts normal myocardium to fatty-acid metabolism so it stops taking up FDG, while inflammatory macrophages remain obligate glucose users and stay FDG-avid. That contrast is what makes the study diagnostic.

What dietary protocol gives the best myocardial suppression?

Published comparisons favor a longer, stricter preparation. A study comparing three protocols reported complete myocardial suppression in about 96.9% of patients with a 72-hour ketogenic diet plus prolonged overnight fasting, versus about 68.1% with a 24-hour ketogenic diet and about 52.3% with 18-hour fasting alone. The SNMMI–ASNC consensus recommends at least a high-fat, low-carbohydrate diet for roughly 24 hours followed by 4 to 12 hours of fasting.

What is measured to quantify cardiac FDG PET?

The most common quantitative metric is the maximum standardized uptake value (SUVmax) in the left ventricular myocardium and in any suspicious lymph nodes, often compared against blood-pool or liver reference values. Some programs also report a metabolic volume or total lesion glycolysis. SUV must be computed consistently, with accurate injected activity, decay correction, patient weight, and a calibrated scanner.

How is the study interpreted for cardiac sarcoidosis?

Interpretation pairs a rest perfusion study with the FDG metabolic study. A region that is normally perfused but FDG-avid, or a perfusion defect that is also FDG-avid (a perfusion–metabolism mismatch), suggests active inflammation. Diffuse uniform uptake usually indicates failed suppression rather than disease, which is why preparation quality is inseparable from interpretation.

What radiation dose does a cardiac FDG PET/CT involve?

Using the ICRP Publication 128 adult effective-dose coefficient for F-18 FDG of about 0.019 mSv per MBq, a typical 370 MBq (10 mCi) injection delivers roughly 7 mSv from the radiopharmaceutical, with an additional contribution from the CT component that depends on whether the CT is low-dose attenuation correction or diagnostic quality.

What QC matters most for cardiac FDG PET quantitation?

SUV accuracy depends on cross-calibration between the dose calibrator and the PET scanner, correct clock synchronization for decay correction, accurate patient weight and injected-activity entry (including residual activity in the syringe and line), and routine scanner normalization and calibration. An error in any of these propagates directly into SUV.

Can the study monitor response to therapy?

Yes. Because FDG uptake reflects active inflammation, serial studies with consistent preparation and quantitation can show whether immunosuppressive therapy is reducing inflammatory activity. Consistent dietary preparation between scans is essential, because a difference in suppression can masquerade as a change in disease.

Key Takeaways

• Preparation is the study. The goal is to suppress normal myocardial glucose use so inflammation stands out; failed suppression makes the scan non-diagnostic.
• Longer, stricter diets suppress better. Complete suppression was reported in about 96.9% with a 72-hour ketogenic preparation versus about 52.3% with 18-hour fasting alone.
• Inflammation is an obligate glucose user. Macrophages keep taking up FDG after normal myocardium switches to fatty acids — that is the contrast mechanism.
• Interpret with perfusion. The perfusion–metabolism mismatch pattern is the diagnostic backbone; diffuse uptake usually means failed prep.
• SUV is only as good as its inputs. Injected activity, residual subtraction, weight, decay correction, and cross-calibration all feed directly into the number.
• Consistency enables therapy monitoring. Serial studies are comparable only when preparation and quantitation are held constant.

Conclusion

Cardiac FDG PET/CT is one of the most valuable studies in cardiac imaging for a disease that is otherwise hard to catch — but its value is entirely contingent on preparation. The physics is a metabolic switch: drive normal myocardium to fatty-acid oxidation so it goes dark, and let obligate-glucose-consuming inflammatory cells shine. ^{1, 2}

A program that treats dietary preparation, glucose checking, injected-activity accounting, and scanner cross-calibration as rigorously as the acquisition itself will produce diagnostic, reproducible, quantitatively trustworthy studies. A program that treats preparation as a patient-instruction afterthought will produce a stream of diffuse, uninterpretable scans. The difference is not the scanner; it is the discipline around it.

How DRPS Can Help

Diagnostic Radiation Physics Services supports cardiac PET programs with PET/CT and nuclear medicine physics services, including scanner-to-dose-calibrator cross-calibration, SUV quantitation QC, protocol review, dose optimization, and accreditation support. Our board-certified physicists help nuclear cardiology and nuclear medicine programs build quantitative PET workflows that are consistent, documented, and defensible.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A cardiac sarcoid PET program succeeds when the preparation is as disciplined as the physics.

Related Resources

• PET SUV quantification
• F-18 FDG PET dose optimization
• PET/CT daily QC and calibration
• Quantitative myocardial blood flow cardiac PET
• Radiopharmaceutical dosimetry and ICRP 128
• PET/CT and nuclear medicine physics services
• Accreditation support

References

1. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of F-18-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med. 2017;58(8):1341-1353. doi:10.2967/jnumed.117.196287. PubMed
2. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of F-18-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24(5):1741-1758. doi:10.1007/s12350-017-0978-9. PubMed
3. Özütemiz C, Koksel Y, Froelich JW, et al. Comparison of the effect of three different dietary modifications on myocardial suppression in F-18-FDG PET/CT evaluation of patients for suspected cardiac sarcoidosis. J Nucl Med. 2021;62(12):1759-1767. doi:10.2967/jnumed.121.261981. PubMed
4. Hutt E, Goldar G, Jaber WA, Cremer PC. Standardized ketogenic dietary preparation for metabolic PET imaging in suspected and known cardiac sarcoidosis. Eur Heart J Imaging Methods Pract. 2024;2(1):qyae037. doi:10.1093/ehjimp/qyae037. PubMed
5. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305-1323. doi:10.1016/j.hrthm.2014.03.043. PubMed
6. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Annals of the ICRP. 2015;44(2S). icrp.org
7. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging — version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328-354. doi:10.1007/s00259-014-2961-x. PubMed
8. Society of Nuclear Medicine and Molecular Imaging. SNMMI Procedure Standards. SNMMI. snmmi.org
9. American Society of Nuclear Cardiology. ASNC Imaging Guidelines and Clinical Guidelines. ASNC. asnc.org